Summary
- Profile Type
- Technology offer
- POD Reference
- TOSK20230807017
- Term of Validity
- 7 August 2023 - 6 August 2025
- Company's Country
- Slovakia
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
A team of inventors from an established Slovak scientific and research institute has developed new technology for determination of congenital disorders of glycosylation (CDG). It is a highly sensitive, simple and rapid method for the primary detection of CDG in blood samples using specially prepared biochips or microplates by evaluating the signal ratio of samples reaction with a specific combination of lectins.
The preferred cooperation type are commercial agreement or investment agreement. - Full Description
-
Glycosylation is a co- and post-translational modification of proteins and lipids important for their physiological function and glycopattern/glyco-epitope changes, which are associated with changes in their biological function involved in many civilizational and metabolic diseases - "Congenital Disorders of Glycosylation (CDG)". Currently, the classic isoelectric focusing (IEF) method of blood transferrin and immunodetection, or mass analysis, was used to detect CDG. However, the IEF-based method cannot capture or determine some subtypes of CDG, because partial glycosylation reactions, such as fucosylation, are unidentifiable by traditional methods. By mass analysis of the released glycoepitopes and derivatization, it is possible to determine their fucosylation, but this method is demanding financially, time-wise, and requires the expertise of the staff. Lectin panels are therefore a suitable and available means for determining CDG even as part of routine screening. The above-mentioned shortcomings are solved by rapid determination of CDG/screening for the possible presence of CDG by determining complex glycoepitopes of a specific biological fluid, serum or plasma, using its denaturation, immobilization on a solid substrate, application of a specific combination of biotinylated lectins and detection using commonly used microplate readers or microarray scanners.
A team of inventors/originators from a Slovak scientific and research institution managed to develop a reliable method of detecting a primary CDG in a human serum or blood plasma sample, which can be denatured based on the analysis of total serum glyco-epitopes using specifically designed biochips or microplates containing immobilized samples and their detection by a specific combination of biotinylated lectins.
The new technology, based on analytical determination in the format of microarray biochips or microplates, will make it possible to determine the difference in glycosylation of sera in the determination of a specific primary deficit in the glycosylation pathway, as well as in other diseases manifested by changes in glycosylation.
The institute is looking for a partner to cooperate with via commercial agreement or investment agreement. - Advantages and Innovations
-
• the possibility of achieving a result easily and quickly,
• the possibility of reducing the requirements for the quantity of the sample,
• the possibility of using commercially available reagents with guaranteed quality,
• the possibility of using commonly available reading devices – microplate readers,
• the possibility of application in automated analyzers,
• low price. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- Pending patent: priority patent application (PP 50002-2023)
Partner Sought
- Expected Role of a Partner
-
The present invention can be used in various fields, specifically in the diagnosis of diseases in which the glycan formula of proteins in the blood changes, especially congenital disorders of glycosylation (CDG).
The speed, sensitivity and simplicity of this technology allows its use also for routine CDG screening.
The institution is looking for a partner to cooperate with via commercial agreement (a partner for licensing of this technology is sought or investment agreement (an investor to further develop this technology is sought or a partner to sell this technology to is sought). - Type and Size of Partner
- SME 50 - 249
- Big company
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06005003 - Health information management
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Targeted countries
- All countries